• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024

    8/8/24 7:10:00 AM ET
    $XTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XTNT alert in real time by email

    BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024.

    Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.

    Conference Details:
    Conference Date: Friday, August 9, 2024
    Conference Time: 9:00 AM ET
    Conference dial-in: 888-999-3182
    International dial-in: 848-280-6330
    Passcode: Xtant Medical Holdings
    Conference Call Name: Xtant Medical Q2 2024 Financial Results
    Webcast Link: https://www.webcaster4.com/Webcast/Page/3039/50961

    Following the live call, a replay will be available on the Company's website, https://xtantmedical.com/, under "Investor Info."

    About Xtant Medical Holdings, Inc.

    Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (https://xtantmedical.com/) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

    The symbols™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

    Investor Relations Contact

    Brett Maas • Managing Partner, Hayden IR
    [email protected] • (646) 536-7331

    SOURCE: Xtant Medical Holdings, Inc.




    View the original press release on accesswire.com

    Get the next $XTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XTNT

    DatePrice TargetRatingAnalyst
    12/5/2023$2.00Buy
    BTIG Research
    More analyst ratings

    $XTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Xtant Medical with a new price target

      BTIG Research initiated coverage of Xtant Medical with a rating of Buy and set a new price target of $2.00

      12/5/23 8:12:02 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XTNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xtant Medical Announces the Launch of OsteoFactor Pro™

      Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont., May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders, today announced the commercial launch of OsteoFactor Pro™, a naturally occurring cocktail of allogeneic growth factors engineered to improve bone healing and support surgical success across orthopedic and spine procedures. OsteoFactor Pro™ is a naturally derived, growth factor-rich formulation that enhances the biologic activity and regenerative potential of any orthobiologic scaffold. Its biphasic release profile—d

      5/28/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical Reports First Quarter 2025 Financial Results

      Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont., May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $32.9 million, up 18%, compared to the prior year quarterGross margin of 61.5% compared to 62.1% for the prior year quarterNet income of $58,000 compared to a net lo

      5/12/25 4:05:00 PM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025

      BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results. Conference Details:Conference Date: Monday, May 12, 2025Conference Time: 4:30 PM ETConference dial-in: 888-506-0062International dial

      5/6/25 8:00:00 AM ET
      $XTNT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care